Multiple Myeloma and Amyloidosis Program

The Multiple Myeloma and Amyloidosis program provides a valuable resource to patients with these conditions. We offer a comprehensive array of services and treatment options based on the specific challenges of each patient's disease characteristics and stage. Through our various clinical trials, patients with multiple myeloma can access leading-edge, novel therapeutics. The clinical trials are complemented by the program’s basic and translational research in several promising areas, including anti-angiogenesis, vaccines, anti-virus treatments, gene therapy and third-generation bisphosphonates.